

From: Mahon, Barbara (CDC/DDID/NCIRD/OD)
Sent: Tue, 31 Aug 2021 21:26:52 +0000
To: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP); Layden, Jennifer (CDC/DDPHSS/OS/OD); Fox, Kimberley (CDC/DDID/NCIRD/DBD); Biagioni, Mark T. (CDC/DDID/NCIRD/DBD)
Subject: RE: v-safe question

Yup, this all makes sense.

(b)(6)

was asking because I knew that VAERS and VSD would already be fine to monitor myocarditis (or appendicitis!) and the like but that v-safe was not configured for third doses in the spring.

Thanks, and thanks for all the great work you and your team have done.

Barbara

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Sent: Tuesday, August 31, 2021 5:19 PM
To: Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>; Layden, Jennifer (CDC/DDPHSS/OS/OD) <qbg5@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>; Biagioni, Mark T. (CDC/DDID/NCIRD/DBD) <gld5@cdc.gov>
Subject: RE: v-safe question

Hi Barbara,

V-safe is structured to monitor 3rd dose, but v-safe will not be particularly useful for monitoring myocarditis. That will primarily be accomplished through VAERS and VSD monitoring. The questions in v-safe are pre-specified and focus on local and systemic reactogenicity and fairly general adverse health impact events. If a patient reports receiving care from a healthcare provider we would follow-up to take a VAERS report so we might capture myocarditis cases that way, but v-safe won't specifically get at myocarditis. It's just not designed to directly monitor specific adverse events outside of reactogenic AEs.

Tom

From: Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Sent: Tuesday, August 31, 2021 5:04 PM
To: Layden, Jennifer (CDC/DDPHSS/OS/OD) <qbg5@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>; Biagioni, Mark T. (CDC/DDID/NCIRD/DBD) <gld5@cdc.gov>
Cc: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Subject: RE: v-safe question

Thanks a million. That's what I wanted to know.

Tom, I know how insanely busy you are—no need to weigh in unless you really want to.

Barbara

From: Layden, Jennifer (CDC/DDPHSS/OS/OD) <qbg5@cdc.gov>
Sent: Tuesday, August 31, 2021 5:02 PM
To: Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>; Biagioni, Mark T. (CDC/DDID/NCIRD/DBD) <gl5@cdc.gov>
Cc: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Subject: RE: v-safe question

Hi there-

It is. The safety team has been getting the various systems ready, and are thinking through a few items.

Adding Tom, who is the lead and guru of vaccine safety, in case he wants to provide more details.

jen

Jen Layden, MD, PhD
Deputy Director, Office of Science
Centers for Disease Control and Prevention
Cell phone: 404-435-2237

From: Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Sent: Tuesday, August 31, 2021 4:57 PM
To: Layden, Jennifer (CDC/DDPHSS/OS/OD) <qbg5@cdc.gov>; Fox, Kimberley (CDC/DDID/NCIRD/DBD) <kaf6@cdc.gov>; Biagioni, Mark T. (CDC/DDID/NCIRD/DBD) <gl5@cdc.gov>
Subject: v-safe question

All,

I bet the answer is yes, but do you know if v-safe is being updated to accommodate third doses of mRNA vaccines? (b)(5)

(b)(5) I'm sure others who know more about vaccine safety than I do are already working on this....

Thanks,

Barbara

*Barbara Mahon, MD, MPH
Deputy Incident Manager
CDC COVID-19 response
+1-470-755-9262*

IR#0960C_000031